The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma

Cancer Research

Volumn 69, Issue 19, 2009, Pages 7662-7671

  Kurmasheva, Raushan T ^a,b   Dudkin, Lorina ^a,b   Billups, Catherine ^a   Debelenko, Larisa V ^a   Morton, Christopher L ^a   Houghton, Peter J ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CP 751871; PROTEIN KINASE B; RAPAMYCIN; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER REGRESSION; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG POTENTIATION; EWING SARCOMA; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RHABDOMYOSARCOMA; SARCOMA; TRANSCRIPTION REGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, SCID; OSTEOSARCOMA; RECEPTOR, IGF TYPE 1; RHABDOMYOSARCOMA; SARCOMA; SARCOMA, EWING'S; SIROLIMUS; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350227313     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1693     Document Type: Article

References (48)

1. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001;11:289-297 (Pubitemid 34257726)
2. Fukuzawa R, Umezawa A, Ochi K, Urano F, Ikeda H, Hata J. High frequency of inactivation of the imprinted H19 gene in "sporadic" hepatoblastoma. Int J Cancer 1999;82:490-497
3. Minniti CP, Tsokos M, Newton WA, Jr., Helman LJ. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am J Clin Pathol 1994;101:198-203. (Pubitemid 24061448)
4. Scotlandi K, Benini S, Nanni P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 1998;58:4127-4131 (Pubitemid 28440569)
5. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4574 (Pubitemid 26338048)
6. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-7283 (Pubitemid 39014452)
7. Pollak M, Richard M. Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 1990;82:1349-1352
8. Bostedt KT, Schmid C, Ghirlanda-Keller C, Olie R, Winterhalter KH, Zapf J. Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells. Exp Cell Res 2001;271:368-377 (Pubitemid 33141218)
9. MacEwen EG, Pastor J, Kutzke J, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004;92:77-91.
10. El-Badry OM, Helman LJ, Chatten J, Steinberg SM, Evans AE, Israel MA. Insulin-like growth factor II-mediated proliferation of human neuroblastoma. J Clin Invest 1991;87:648-657
11. Weber A, Huesken C, Bergmann E, Kiess W, Christiansen NM, Christiansen H. Coexpression of insulin receptor-related receptor and insulin-like growth factor 1 receptor correlates with enhanced apoptosis and dedifferentiation in human neuroblastomas. Clin Cancer Res 2003;9:5683-5692 (Pubitemid 37499491)
12. Sandberg AC, Engberg C, Lake M, von Holst H, Sara VR. The expression of insulin-like growth factor I and insulin-like growth factor II genes in the human fetal and adult brain and in glioma. Neurosci Lett 1988;93:114-119 (Pubitemid 18255849)
13. Resnicoff M, Li W, Basak S, Herlyn D, Baserga R, Rubin R. Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Cancer Immunol Immunother 1996;42:64-68 (Pubitemid 26069865)
14. Antoniades HN, Galanopoulos T, Neville-Golden J, Maxwell M. Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 1992;50:215-222
15. Del Valle L, Enam S, Lassak A, et al. Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res 2002;8:1822-1830 (Pubitemid 34633741)
16. Hirschfeld S, Helman L. Diverse roles of insulin-like growth factors in pediatric solid tumors. In vivo (Athens, Greece) 1994;8:81-90. (Pubitemid 24156538)
17. Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003;35:685-693
18. Braczkowski R, Schally AV, Plonowski A, et al. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer 2002;95:1735-1745 (Pubitemid 35153465)
19. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11:2063-2073
20. Wang Y, Hailey J, Williams D, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 2005;4:1214-1221 (Pubitemid 41149569)
21. Guerreiro AS, Boller D, Doepfner KT, Arcaro A. IGF-IR: potential role in antitumor agents. Drug News Perspect 2006;19:261-272 (Pubitemid 44186589)
22. Kurmasheva RT, Houghton PJ. IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 2006;1766:1-22.
23. Sachdev D, Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 2006;11:27-39. (Pubitemid 44309187)
24. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12. (Pubitemid 46206663)
25. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003;63:627-635 (Pubitemid 36158140)
26. Goetsch L, Gonzalez A, Leger O, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005;113:316-328 (Pubitemid 39628325)
27. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484
28. Bjornsti MA, Houghton PJ. The TORpathway : a target for cancer therapy. Nat Rev Cancer 2004;4:335-348
29. Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res 1994;54:903-907 (Pubitemid 24085438)
30. Houchens DP, Ovejera AA, Riblet SM, Slagel DE. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 1983;19:799-805.
31. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:799-805. (Pubitemid 351354788)
32. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2006;49:928-940 (Pubitemid 350022448)
33. Meyer WH, Houghton JA, Houghton PJ, Webber BL, Douglass EC, Look AT. Development and characterization of pediatric osteosarcoma xenografts. Cancer Res 1990;50:2781-2785
34. Thimmaiah KN, Easton J, Huang S, et al. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling pathways. Cancer Res 2003;63:364-374 (Pubitemid 36152494)
35. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001;7:1758-1764 (Pubitemid 32708646)
36. Kurmasheva RT, Harwood FC, Houghton PJ. Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther 2007;6:1620-1628
37. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007;49:928-940 (Pubitemid 350022448)
38. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4:1533-1540 (Pubitemid 41556435)
39. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508 (Pubitemid 43259931)
40. Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor i receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008;68:8039-8048
41. Whiteford CC, Bilke S, Greer BT, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 2007;67:32-40. (Pubitemid 46142757)
42. Neale G, Su X, Morton CL, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008;14:4572-4583
43. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1190-1197 (Pubitemid 351555543)
44. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-1610
45. Arsham AM, Plas DR, Thompson CB, Simon MC. Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res 2004;64:3500-3507
46. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002;16:771-780 (Pubitemid 34615125)
47. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601. (Pubitemid 38796850)
48. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-135 (Pubitemid 34155123)